Related Experiment Video
Updated: Jul 5, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Alterations in plasma soluble vascular endothelial growth factor receptor-1 (sFlt-1) concentrations during coronary
Yves Denizot1, Alexandre Leguyader, Elisabeth Cornu
1UMR CNRS 6101, Centre National de la Recherche Scientifique, Université de Limoges, France. yves.denizot@unilim.fr
Insights
Lowered plasma levels of soluble fms-like tyrosine kinase-1 (sFlt-1) during extracorporeal circulation (ECC) are associated with post-coronary artery bypass graft (CABG) complications. This suggests sFlt-1 may be a target for reducing adverse effects.
Area of Science:
- Cardiovascular Surgery
- Neovascularization Biology
- Clinical Chemistry
Background:
- Plasma concentrations of soluble fms-like tyrosine kinase-1 (sFlt-1) increase during coronary artery bypass graft (CABG) surgery with extracorporeal circulation (ECC).
- The relationship between sFlt-1 levels and post-CABG surgical complications requires further investigation.
Purpose of the Study:
- To investigate the association between plasma sFlt-1 levels and the occurrence of surgical complications following CABG.
- To determine if sFlt-1 levels can predict adverse outcomes after CABG surgery.
Main Methods:
- Plasma samples were collected from 31 patients undergoing CABG at multiple time points.
- sFlt-1 levels were measured using commercially available ELISA kits.
- Cardiovascular, haematological, and respiratory dysfunctions were prospectively assessed.
Main Results:
- Patients who developed post-CABG complications showed significantly lower plasma sFlt-1 levels at the end of ECC compared to those with uneventful surgery.
- Lowered sFlt-1 levels were specifically associated with haematological and cardiovascular impairments, but not respiratory complications.
- Pre-operative sFlt-1 levels did not differ between patients with and without complications.
Conclusions:
- An association exists between specific post-CABG complications and reduced sFlt-1 release during ECC.
- sFlt-1-mediated vascular endothelial growth factor (VEGF) neutralization may offer a therapeutic strategy to mitigate post-operative adverse effects after CABG.
Background:
Plasma concentrations of sFlt-1, the soluble form of the vascular endothelial growth factor receptor (VEGF), markedly increase during coronary artery bypass graft (CABG) surgery with extracorporeal circulation (ECC). We investigated if plasma sFlt-1 values might be related to the occurrence of surgical complications after CABG.
Methods:
Plasma samples were collected from the radial artery catheter before vascular cannulation and after opening the chest, at the end of ECC just before clamp release, after cross release, after weaning from ECC, at the 6th and 24th post-operative hour. Thirty one patients were investigated. The presence of cardiovascular, haematological and respiratory dysfunctions was prospectively assessed. Plasma sFlt-1 levels were measured with commercially ELISA kits.
Results:
Among the 31 investigated patients, 15 had uneventful surgery. Patients with and without complications had similar pre-operative plasma sFlt-1 levels. Lowered plasma sFlt-1 levels were observed at the end of ECC in patients with haematological (p = 0.001, ANOVA) or cardiovascular (p = 0.006) impairments, but not with respiratory ones (p = 0.053), as compared to patients with uneventful surgery.
Conclusion:
These results identify an association between specific post-CABG complication and the lower release of sFlt-1 during ECC. sFlt-1-induced VEGF neutralisation might, thus, be beneficial to reduce the development of post-operative adverse effects after CABG.
